Centers for AIDS Research (P30 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Centers for AIDS Research (CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. CFARs provide core facilities, expertise, resources, and services not readily obtained otherwise through more traditional funding mechanisms. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research.Peter J. Perrin, Ph.D. | PAR-20-106 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - February 3, 2020 Category: Endocrinology Source Type: funding
Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Biostatistics Research Center (BRC) (Collaborative U01 Clinical Trial Required)
The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to continue follow-up of the Diabetes Prevention Program Outcomes Study (DPPOS) cohort through a collaborative cooperative agreement. The Diabetes Prevention Program (DPP) was a multi-center controlled clinical trial examining the efficacy of treatments to prevent or delay the development of type 2 diabetes in a population at high risk. The DPP demonstrated that either weight loss through lifestyle change or the drug metformin could reduce the development of type 2 diabetes by 58% and 31%, respectively, compared with placebo. Following the en...
Source: NIDDK Funding Opportunities - January 23, 2020 Category: Endocrinology Source Type: funding
Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Clinical Centers (Collaborative U01 Clinical Trial Required)
The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to continue follow-up of the Diabetes Prevention Program Outcomes Study (DPPOS) cohort through a collaborative cooperative agreement. The Diabetes Prevention Program (DPP) was a multi-center controlled clinical trial examining the efficacy of treatments to prevent or delay the development of type 2 diabetes in a population at high risk. The DPP demonstrated that either weight loss through lifestyle change or the drug metformin could reduce the development of type 2 diabetes by 58% and 31%, respectively, compared with placebo. Following the en...
Source: NIDDK Funding Opportunities - January 23, 2020 Category: Endocrinology Source Type: funding
Urology Centers Program Interactions Core (U24 Clinical Trial Not Allowed)
The George M. O'Brien Urology Research Centers (U54) and Exploratory Centers for Interdisciplinary Research in Benign Urology (P20) serve to advance the NIDDKs mission to support highly meritorious, innovative, interdisciplinary research in benign urologic diseases and disorders, and the training of the next generation of researchers. Critical to these broad goals is the ability to promote productive interactions between the U54 and P20 Centers, the institutional career development programs (K12), and the broader urology research and clinical communities. The purpose of this Funding Opportunity Announcement (FOA) is to sol...
Source: NIDDK Funding Opportunities - January 21, 2020 Category: Endocrinology Source Type: funding
KUH Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)
The purpose of the Kidney, Urology or Hematology (KUH) Predoctoral to Postdoctoral Fellow Transition Awards (F99/K00) is to recruit exceptional graduate students from diverse research fields to pursue postdoctoral training focused on Kidney, Urology or Hematology (K, U, or H) research. Talented graduate students from disciplines including, but not limited to, engineering, statistics, data science, imaging, biochemistry and genetics are invited to apply to this opportunity. Graduate students who are already involved in K, U, or H research are not eligible for the F99/K00 award and are instead encouraged to apply for the Rut...
Source: NIDDK Funding Opportunities - January 16, 2020 Category: Endocrinology Source Type: funding
Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research addressing barriers that limit progress toward effective open- and closed-loop glucose control systems. Proposed research should tackle important obstacles at the level of sensing, hormone formulation and delivery, self-management decision support systems, and/or design of automated controllers/algorithms able to manage an integrated platform. This research may contribute to development of affordable and user friendly technologies to improve glucose control in patients with type 1 diabetes.Guiller...
Source: NIDDK Funding Opportunities - January 2, 2020 Category: Endocrinology Source Type: funding
New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed)
The New Investigator Gateway Award in T1D Research is designed to ensure that a robust pipeline of talented new investigators will continue to embark on successful careers in T1D research. In addition to providing support for preliminary research, the Gateway program provides an opportunity for new PIs to pursue their studies within the intellectual environment of a select number of large, ongoing collaborative research programs. Embedding awardees within an established scientific framework in each of these consortia will provide unique opportunities for New andEarly Stage Investigators to increase their understanding of k...
Source: NIDDK Funding Opportunities - January 2, 2020 Category: Endocrinology Source Type: funding
Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas [HIRN Consortium on Beta Cell Death and Survival (CBDS)] (U01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) requests applications to explore human pancreatic tissues for the discovery of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the discovery of early biomarkers of T1D pathogenesis, the development of diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification and biological validation of therapeutic targets for the development of preventative or early treatment strategies. Successful applicants will join the Consortium on Beta Cell Death and Survival (CBDS), wh...
Source: NIDDK Funding Opportunities - January 2, 2020 Category: Endocrinology Source Type: funding
Treating Diabetes Distress to Improve Glycemic Outcomes in Type 1 Diabetes (R01 Clinical Trial Required)
This FOA seeks applications for clinical trials testing interventions targeting diabetes distress in individuals with type 1 diabetes and/or their caregivers, with the goal of understanding whether lowering diabetes distress will improve glycemic control and quality of life. Given the clinical care recommendation that screening for diabetes distress take place in the context of medical care, applications should reflect a practical team approach to screening and treatment that could realistically occur in a clinical setting.RFA-DK-19-021 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - January 2, 2020 Category: Endocrinology Source Type: funding
Notice of Special Interest (NOSI): Addressing Health Disparities in NIDDK Diseases
The overall objective of this NOSI is to understand and mitigate health disparities in the development, diagnosis, and treatment of diseases of high priority to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). It is recognized that both biologic and non-biologic factors may be operating in these underserved populations.Robert Rivers, Ph.D. | NOT-DK-20-003 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - December 16, 2019 Category: Endocrinology Source Type: funding
Limited Competition: NIDDK Program Projects (P01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Research Program Project Grant (P01) renewal (Type 2) applications. The proposed programs should address scientific areas relevant to the NIDDK mission including diabetes, selected endocrine and metabolic diseases, obesity, digestive diseases and nutrition, and kidney, urologic and hematologic diseases, as well as new approaches to prevent, treat and cure these diseases, including clinical research. A description of NIDDK scientific program areas can be found at https://www.niddk.nih.gov/about-niddk/research-areas.National Institute of...
Source: NIDDK Funding Opportunities - December 11, 2019 Category: Endocrinology Source Type: funding
Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of novel and supportive technologies for the improvement of cell replacement interventions using novel methods, biomaterials and devices for type 1 diabetes (T1D) treatment.RFA-DK-19-028 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - December 10, 2019 Category: Endocrinology Source Type: funding
Type 1 Diabetes in Acute Pancreatitis Consortium - Data Coordinating Center (T1DAPC-DCC) (U01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) solicits U01 applications for the establishment of a clinical consortium, the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC), composed of one Data Coordinating Center (DCC) and up to 10 Clinical Centers (CC), to conduct studies on Type 1 diabetes mellitus (T1D) that occurs after or as a consequence of one or more episodes of acute pancreatitis. Applications for the Clinical Centers (CC) are submitted in response to a separate FOA: RFA-DK-19-022: Type 1 Diabetes in Acute Pancreatitis Consortium Clinical Centers (T1DAPC-CC) (U01). The applicant for the Data Coordinating ...
Source: NIDDK Funding Opportunities - December 9, 2019 Category: Endocrinology Source Type: funding
Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers (T1DAPC-CCs) (U01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) solicits U01 applications for the establishment of a clinical consortium, composed of one Data Coordinating Center (DCC) and up to 10 Clinical Centers (CC), to conduct studies on diabetes mellitus, with an emphasis on Type 1 diabetes (T1D), that occurs after or as a consequence of one or more episodes of acute pancreatitis. The Consortium will form multi-disciplinary teams composed of members from the CCs and DCC to undertake a prospective longitudinal observational study of the occurrence of diabetes that occurs during an acute pancreatitis episode or subsequently, with an empha...
Source: NIDDK Funding Opportunities - December 9, 2019 Category: Endocrinology Source Type: funding
Clinical Trials to Test Artificial Pancreas Device Systems in Populations Challenging to Manage Type 1 Diabetes (T1D) (U01 Clinical Trial Required)
This FOA will support the conduct of clinical trials designed to test the clinical safety and efficacy of artificial pancreas (AP) device systems with the objective of improving glycemic control, reducing acute complications and improving quality of life in people with difficult to control T1D when using standard of care therapies.RFA-DK-19-036 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - December 4, 2019 Category: Endocrinology Source Type: funding
